Nicotinsaeure-codeinester | 3688-66-2

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 吗啡烷
• 英文名称: Nicotinsaeure-codeinester
• 英文别名: 4,5α-epoxy-3-methoxy-17-methyl-6α-nicotinoyloxy-morphin-7-ene；Codeine nicotinate；(9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl) pyridine-3-carboxylate
• CAS: 3688-66-2
• 化学式: C₂₄H₂₄N₂O₄
• 分子量: 404.466
• InChiKey: RYBGRHAWFUVMST-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  60.9
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
  申请人：Scaramuzzino, Giovanni

  公开号：EP1336602A1

  公开（公告）日：2003-08-20

  New pharmaceutical compounds of general formula (I): F-(X)q where q is an integer from 1 to 5, preferably 1; -F is chosen among drugs described in the text, -X is chosen among 4 groups -M, -T, -V and -Y as described in the text. The compounds of general formula (I) are nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without hypotensive side effects and for this reason they are useful for the preparation of medicines for prevention and treatment of inflammatory, ischemic, degenerative and proliferative diseases of musculoskeletal, tegumental, respiratory, gastrointestinal, genito-urinary and central nervous systems.

  通式（I）的新药物化合物：F-（X）q，其中q是1到5的整数，最好是1；-F是在文本中描述的药物中选择的，-X是在文本中描述的4个组-M，-T，-V和-Y中选择的。通式（I）的化合物是硝酸盐前药，可以在体内以受控和选择性的方式释放一氧化氮，而不会产生降压副作用，因此它们非常适用于制备用于预防和治疗肌肉骨骼，皮肤，呼吸，消化，泌尿和中枢神经系统的炎症，缺血，退行性和增生性疾病的药物。
• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• Controlled release formulation with continuous efficacy
  申请人：Egalet Ltd.

  公开号：EP2700400A1

  公开（公告）日：2014-02-26

  The present invention relates to pharmaceutical compositions, which provide controlled release of a drug. The compositions are suitable for continuous administration as they remain effective throughout the treatment regimen. The present invention also relates to the use of the compositions for preparation of a medicament for continuous treatment of an individual.

  本发明涉及可控制药物释放的药物组合物。这些组合物适合连续给药，因为它们在整个治疗过程中都能保持有效。本发明还涉及使用这些组合物制备用于对个人进行连续治疗的药物。
• Pharmaceutical compositions resistant to abuse
  申请人：Egalet Ltd.

  公开号：US10105321B2

  公开（公告）日：2018-10-23

  The present invention provides immediate release pharmaceutical compositions for oral administration that are resistant to abuse.

  本发明提供了抗滥用的口服速释药物组合物。
• Abuse-deterrent controlled release formulations
  申请人：PATHEON SOFTGELS INC.

  公开号：US10182992B2

  公开（公告）日：2019-01-22

  Described herein are abuse deterrent controlled release oral pharmaceutical compositions comprising and methods for making the same. In particular, an abuse deterrent controlled release oral pharmaceutical composition comprising a soft capsule and an abuse deterrent controlled release matrix comprising an active pharmaceutical ingredient are described.

  本文描述的是由阻断药物滥用的控释口服药物组合物及其制造方法。特别是描述了一种包含软胶囊和包含活性药物成分的滥用威慑控释基质的滥用威慑控释口服药物组合物。

表征谱图